Search Result

Results for "

PET imaging

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (2) Amino Acid Derivatives (2) Amyloid-β (4) Apoptosis (1) Bacterial (1) Biochemical Assay Reagents (15) Bombesin Receptor (1) Carbonic Anhydrase (2) Cholecystokinin Receptor (1) CXCR (2) Cytochrome P450 (1) Dopamine Receptor (1) Drug Derivative (1) Drug Intermediate (3) Drug Metabolite (1) EGFR (1) Epigenetic Reader Domain (1) FAAH (1) FAP (3) Fluorescent Dye (3) Galectin (1) HSP (1) Integrin (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) mAChR (2) MAGL (1) Melanocortin Receptor (2) mGluR (2) Microtubule/Tubulin (2) Neurokinin Receptor (1) PARP (2) PSMA (8) Radionuclide-Drug Conjugates (RDCs) (21) Reference Standards (1) RIP kinase (2) Ser/Thr Protease (1) Sigma Receptor (2) Somatostatin Receptor (2) Src (1) Stearoyl-CoA Desaturase (SCD) (1) Tau Protein (3) α-synuclein (1)
By Research Areas:	Cancer (48) Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (1) Neurological Disease (23)
Click Chemistry:	BCN (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Biochemical Assay Reagents	Cancer
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-136404

Melanin probe-1	Fluorescent Dye	Cancer
Melanin probe-1 is an ¹⁸F-picolinamides based PET probe. Melanin probe-1 can be used for PET imaging of malignant melanoma. Melanin probe-1 exhibits high tumor targeting efficiency, excellent tumor imaging contrasts, desirable biodistribution patterns, and good in vivo stability .

HY-153550

PSMA-1007	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. ¹⁸F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P2336A

CCZ01048 TFA 2 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-141464

Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH Fmoc-Asn(Ac3AcNH-beta-Glc)-OH	Amino Acid Derivatives	Cancer
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .

HY-W755222

(S)-NODAGA-tris(t-Bu ester) (S)-NODAG	Biochemical Assay Reagents	Cancer
(S)-NODAGA-tris(t-Bu ester) ((S)-NODAG) is a NODAGA derivative. (S)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-W591317

(R)-NODAGA-tris(t-Bu ester) (R)-NODAG	Radionuclide-Drug Conjugates (RDCs)	Cancer
(R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-D2343

PB0822	Biochemical Assay Reagents	Neurological Disease
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

HY-D2334

AlF-NOTA-c-d-VAP	Radionuclide-Drug Conjugates (RDCs) HSP	Cancer
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-163545

Tc-Me2P	Drug Derivative	Cancer
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-134418

NOTA	Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

HY-101181

THK-5105	Microtubule/Tubulin	Neurological Disease
THK-5105, an arylquinoline derivative, displays high binding affinity to tau fibrils. THK-5105 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD) brain homogenates. 18F-THK-5105 has the potential to act as a tau imaging PET probe .

HY-101182

THK-5117	Microtubule/Tubulin	Neurological Disease
THK-5117, an arylquinoline derivative, displays high binding affinity to tau fibrils with a K_i of 10.5 nM. THK-5117 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD) brain homogenates. 18F-THK-5117 has the potential to act as a tau imaging PET probe .

HY-134418R

NOTA (Standard)	Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
NOTA (Standard) is the analytical standard of NOTA. This product is intended for research and analytical applications. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-156982

Parpi	Others	Cancer
Parpi is a PET radioactive tracer with low lipotropy. Parpi can be used as a tumor imaging agent .

HY-W700684

N-Didesmethyl Loperamide R 21345	Drug Metabolite	Others
N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.

HY-105252A

BF 227	Amyloid-β	Neurological Disease
BF 227 is a candidate for an amyloid imaging probe for PET, with a K_i of 4.3 nM for Aβ1-42 fibrils.

HY-141804

ER176	Biochemical Assay Reagents	Neurological Disease
ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

HY-155483

PSMA-BCH NOTA-PSMA	Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools .

HY-163075

SYB4	Sigma Receptor	Others
SYB4 (compound 5) is a PET tracer which suitable for imaging the Sigma-2 Receptor in the brain of nonhuman primates .

HY-170749

DFO-BCN	Drug Intermediate	Others
DFO-BCN is a drug intermediate, that can be used for synthesis of PET/CT imaging agent DFO-CPC634 through click chemistry .

HY-101185

T808	Tau Protein	Neurological Disease
T808 is a tau-selective Alzheimer’s PET ligand. T808 is a type of imaging agent used in positron emission tomography (PET) scans. It is a radiotracer that is used to help visualize certain areas of the body, such as the brain, in order to diagnose and monitor various medical conditions .

HY-128890

DOTA-NHS-ester 1 Publications Verification	ADC Linker	Cancer
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .

HY-173319

FAP-IN-5	FAP	Cancer
FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC₅₀ of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging .

HY-D2310

CXCR2 Probe 1	CXCR	Inflammation/Immunology
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-129650

Flobetapir 1 Publications Verification AV-45	Biochemical Assay Reagents	Others
Flobetapir (AV-45) may be a well-tolerated imaging agent. Flobetapir synthesizes Florbetapir (18F) that is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18 .

HY-110141

ABP688	mGluR	Others
ABP688 is a high affinity human mGluR5 antagonist with anK_i of 1.7 nM. Radioisotope-labeled ABP688 can be used as a PET tracer for clinical imaging of the mGlu5 receptor .

HY-169107

RIPK1-IN-25	RIP kinase	Neurological Disease
RIPK1-IN-25 (WL8) is a blood-brain permeable RIPK1 inhibitor with EC₅₀ and K_d values are 19.9 and 25 nM, respectively. RIPK1-IN-25 can be used in the study of neurometabolic diseases .

HY-160607

MMA-NODAGA	Radionuclide-Drug Conjugates (RDCs)	Others
MMA-NODAGA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA can be used to conjugate with exosome and ⁶⁴Cu in image with positron emission tomography (PET) ^<[2].

HY-155033

SSI-4	Stearoyl-CoA Desaturase (SCD)	Others
SSI-4 is an inhibitor of Stearoyl CoA desaturase 1 (SCD1) , which can be modified with ¹¹C, used as a ligand to in vivo small animal PET/CT imaging of SCD1 .

HY-W724743

Losartan azide	Biochemical Assay Reagents	Cardiovascular Disease
Losartan azide is a click chemistry reagent containing an azide group and is a synthetic intermediate for the preparation of angiotensin AT1R-targeted renal PET imaging probe [18 F]fluoropyridine-losartan .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-113719

VM4-037	Carbonic Anhydrase	Cancer
VM4-037 can be used for the synthesis of VM4-037(18F). VM4-037(18F) is a fluorinated PET imaging agent for carbonic anhydrase IX .

HY-149869

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

HY-W422400

Fluoroglutamine (2S,4R)	Biochemical Assay Reagents	Others Cancer
Fluoroglutamine (2S,4R) is a fluorinated derivative of glutamine. As a substrate for various aminotransferases, Fluoroglutamine (2S,4R) can be used as a tracer for positron emission tomography (PET) imaging. Fluoroglutamine (2S,4R) is applied in the research fields of tumor metabolism and imaging .

HY-159602

BET BD2-IN-3	Epigenetic Reader Domain	Cancer
BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .

HY-100275

MK-3328	Amyloid-β	Neurological Disease
MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM. MK-3328 is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-172205

CHL2310	Cytochrome P450	Cancer
CHL2310 is the inhibitor for CYP46A1 with an IC₅₀ of 0.11 nM, and a K_d of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive ¹⁸F .

HY-137002

Fmoc-N-Me-Arg(Pbf)-OH	Amino Acid Derivatives	Others
Fmoc-N-Me-Arg(Pbf)-OH is an amino acid derivative containing a guanidinium protecting group on the arginine side chain. Fmoc-N-Me-Arg(Pbf)-OH is used in the synthesis of neurotensin-derived NTS1 ligands for PET imaging .

HY-129650R

Flobetapir (Standard) AV-45 (Standard)	Biochemical Assay Reagents Reference Standards	Others
Flobetapir (Standard) (AV-45 (Standard)) is the analytical standard of Flobetapir (HY-129650). This product is intended for research and analytical applications. Flobetapirmay is a well-tolerated imaging agent. Flobetapir synthesizes Florbetapir (18F) that is a PET scanning radiopharmaceutical compound.

HY-153549

Pentixafor	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-123788

BRD5814	Dopamine Receptor	Neurological Disease
BRD5814 is a D2R antagonist. BRD5814 can be used in schizophrenia research .

HY-101186

MK-6240 1 Publications Verification	Tau Protein	Neurological Disease
MK-6240 is a blood-brain barrier-permeable positron emission tomography (PET) tracer targeting neurofibrillary tangles (NFTs) (K_d = 0.42 nM). MK-6240 can be used for imaging neurofibrillary tangle pathology in Alzheimer's disease and hereditary frontotemporal dementia .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-169868

NOTA-FAPI-52	Biochemical Assay Reagents	Cancer
NOTA-FAPI-52 is a tracer with potent tumor uptake. NOTA-FAPI-52 can be radiolabeled to enable PET imaging or other bioimaging techniques. NOTA-FAPI-52 can be used to study diseases in which fibroblast activation protein (FAP) is overexpressed .

Cat. No.	Product Name	Type

HY-D2343

PB0822	Dyes
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

HY-D2334

AlF-NOTA-c-d-VAP	Dyes
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-D2310

CXCR2 Probe 1	Dyes
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

Cat. No.	Product Name	Type

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Chelators
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-19997

Mannose triflate TATM	Carbohydrates
Mannose triflate is a glucose analog. Mannose triflate is a precursor for 18F-FDG synthesis for PET applications. Mannose triflate binds to 18F via SN2 nucleophilic substitution reaction. Mannose triflate can be used for an imaging technique in detection of cancer .

HY-W130177

Iodocholine iodide	Biochemical Assay Reagents
Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .

HY-141637

2-Deoxy-2-fluoro-D-glucose

1 Publications Verification

2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose

Carbohydrates

2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.

Cat. No.	Product Name	Target	Research Area

HY-153550

PSMA-1007	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. ¹⁸F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P2336A

CCZ01048 TFA 2 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-137002

Fmoc-N-Me-Arg(Pbf)-OH	Amino Acid Derivatives	Others
Fmoc-N-Me-Arg(Pbf)-OH is an amino acid derivative containing a guanidinium protecting group on the arginine side chain. Fmoc-N-Me-Arg(Pbf)-OH is used in the synthesis of neurotensin-derived NTS1 ligands for PET imaging .

HY-153549

Pentixafor	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10744

BQ7859	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-20167A

H-Glu(OtBu)-OtBu hydrochloride	Neurokinin Receptor	Cancer
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P5018

NOTA-AE105	Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease	Cancer
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by ⁶⁴Cu and ⁶⁸Ga. ⁶⁸Ga-NOTA-AE105 and ⁶⁴Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Cat. No.	Product Name	Chemical Structure

HY-141637S1

2-Deoxy-2-fluoro-D-glucose-13C,d7

2-Deoxy-2-fluoro-D-glucose- ¹³C,d₇ is the ¹³C-labeled and deuterium labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637) . 2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.

Cat. No.	Product Name		Classification

HY-170749

DFO-BCN		BCN
DFO-BCN is a drug intermediate, that can be used for synthesis of PET/CT imaging agent DFO-CPC634 through click chemistry .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: